Omeros (OMER) Free Cash Flow (2010 - 2026)
Omeros recorded quarterly Free Cash Flow of -$14.5 million in Q1 2026, up 63.59% quarter-over-quarter from -$39.8 million in Q4 2025, and up 59.57% year-over-year from -$9.1 million in Q1 2025.
Omeros' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$14.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 59.57% year-over-year to -$14.5 million; the TTM figure through Mar 2026 stood at -$94.8 million (up 33.72% YoY), while the FY2025 annual figure was -$116.2 million, up 22.02% from the prior year.
- Free Cash Flow came in at -$14.5 million for Q1 2026 at Omeros, up from -$39.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $174.5 million in Q1 2023 to a low of -$46.1 million in Q2 2024.
- A 5-year average of -$17.2 million and a median of -$29.0 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow surged 1248.81% in 2023 and plunged 123.97% in 2024, its largest moves.
- Omeros' Free Cash Flow stood at -$25.4 million in 2022, then slumped by 37.6% to -$34.9 million in 2023, then rose by 16.99% to -$29.0 million in 2024, then sank by 37.36% to -$39.8 million in 2025, then jumped by 63.59% to -$14.5 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$14.5 million, -$39.8 million, and -$18.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | -14.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.51 Mn |
| Mar 31, 2026 | -14.51 Mn |
| Dec 31, 2025 | -39.84 Mn |
| Dec 31, 2025 | -39.84 Mn |
| Sep 30, 2025 | -18.46 Mn |
| Sep 30, 2025 | -18.46 Mn |
| Jun 30, 2025 | -21.97 Mn |
| Jun 30, 2025 | -21.97 Mn |
| Mar 31, 2025 | -35.88 Mn |
| Mar 31, 2025 | -35.88 Mn |
| Dec 31, 2024 | -29.01 Mn |
| Dec 31, 2024 | -29.01 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Sep 30, 2024 | -32.06 Mn |
| Jun 30, 2024 | -46.07 Mn |
| Jun 30, 2024 | -46.07 Mn |
| Mar 31, 2024 | -41.84 Mn |
| Mar 31, 2024 | -41.84 Mn |
| Dec 31, 2023 | -34.94 Mn |
| Dec 31, 2023 | -34.94 Mn |
| Sep 30, 2023 | -32.68 Mn |
| Sep 30, 2023 | -32.68 Mn |
| Jun 30, 2023 | -32.62 Mn |
| Jun 30, 2023 | -32.62 Mn |
| Mar 31, 2023 | 174.54 Mn |
| Mar 31, 2023 | 174.54 Mn |
| Dec 31, 2022 | -25.40 Mn |
| Dec 31, 2022 | -25.40 Mn |
| Sep 30, 2022 | -26.44 Mn |
| Sep 30, 2022 | -26.44 Mn |
| Jun 30, 2022 | -19.47 Mn |
| Jun 30, 2022 | -19.47 Mn |
| Mar 31, 2022 | -15.19 Mn |
| Mar 31, 2022 | -15.19 Mn |
| Dec 31, 2021 | -18.29 Mn |
| Dec 31, 2021 | -18.29 Mn |
| Sep 30, 2021 | -23.76 Mn |
| Sep 30, 2021 | -23.76 Mn |
| Jun 30, 2021 | -27.68 Mn |
| Jun 30, 2021 | -27.68 Mn |
| Mar 31, 2021 | -40.27 Mn |
| Mar 31, 2021 | -40.27 Mn |
| Dec 31, 2020 | -18.41 Mn |
| Dec 31, 2020 | -18.41 Mn |
| Sep 30, 2020 | -35.01 Mn |
| Sep 30, 2020 | -35.01 Mn |
| Jun 30, 2020 | -37.74 Mn |
| Jun 30, 2020 | -37.74 Mn |
| Mar 31, 2020 | -9.21 Mn |
| Mar 31, 2020 | -9.21 Mn |
| Dec 31, 2019 | -23.03 Mn |
| Dec 31, 2019 | -23.03 Mn |
| Sep 30, 2019 | -7.56 Mn |
| Sep 30, 2019 | -7.56 Mn |
| Jun 30, 2019 | -16.69 Mn |
| Jun 30, 2019 | -16.69 Mn |
| Mar 31, 2019 | -13.13 Mn |
| Mar 31, 2019 | -13.13 Mn |
| Dec 31, 2018 | -24.75 Mn |
| Dec 31, 2018 | -24.75 Mn |
| Sep 30, 2018 | -36.96 Mn |
| Sep 30, 2018 | -36.96 Mn |
| Jun 30, 2018 | -31.11 Mn |
| Jun 30, 2018 | -31.11 Mn |
| Mar 31, 2018 | -11.48 Mn |
| Mar 31, 2018 | -11.48 Mn |
| Dec 31, 2017 | -4.17 Mn |
| Dec 31, 2017 | -4.17 Mn |
| Sep 30, 2017 | -11.23 Mn |
| Sep 30, 2017 | -11.23 Mn |
| Jun 30, 2017 | -8.40 Mn |
| Jun 30, 2017 | -8.40 Mn |
| Mar 31, 2017 | -12.77 Mn |
| Mar 31, 2017 | -12.77 Mn |
| Dec 31, 2016 | -10.91 Mn |
| Dec 31, 2016 | -10.91 Mn |
| Sep 30, 2016 | -11.26 Mn |
| Sep 30, 2016 | -11.26 Mn |
| Jun 30, 2016 | -12.83 Mn |
| Jun 30, 2016 | -12.83 Mn |
| Mar 31, 2016 | -16.63 Mn |
| Mar 31, 2016 | -16.63 Mn |
| Dec 31, 2015 | -16.65 Mn |
| Dec 31, 2015 | -16.65 Mn |
| Sep 30, 2015 | -14.66 Mn |
| Sep 30, 2015 | -14.66 Mn |
| Jun 30, 2015 | -16.66 Mn |
| Jun 30, 2015 | -16.66 Mn |
| Mar 31, 2015 | -17.48 Mn |
| Mar 31, 2015 | -17.48 Mn |
| Dec 31, 2014 | -15.71 Mn |
| Dec 31, 2014 | -15.71 Mn |
| Sep 30, 2014 | -15.95 Mn |
| Sep 30, 2014 | -15.95 Mn |
| Jun 30, 2014 | -15.27 Mn |
| Jun 30, 2014 | -15.27 Mn |
| Mar 31, 2014 | -11.15 Mn |
| Mar 31, 2014 | -11.15 Mn |
| Dec 31, 2013 | -363,000.00 |
| Dec 31, 2013 | -363,000.00 |
| Sep 30, 2013 | -11.09 Mn |
| Sep 30, 2013 | -11.09 Mn |
| Jun 30, 2013 | -9.39 Mn |
| Jun 30, 2013 | -9.39 Mn |
| Mar 31, 2013 | -9.06 Mn |
| Mar 31, 2013 | -9.06 Mn |
| Dec 31, 2012 | -13.19 Mn |
| Dec 31, 2012 | -13.19 Mn |
| Sep 30, 2012 | -7.49 Mn |
| Sep 30, 2012 | -7.49 Mn |
| Jun 30, 2012 | -8.93 Mn |
| Jun 30, 2012 | -8.93 Mn |
| Mar 31, 2012 | -5.58 Mn |
| Mar 31, 2012 | -5.58 Mn |
| Dec 31, 2011 | -7.40 Mn |
| Dec 31, 2011 | -7.40 Mn |
| Sep 30, 2011 | -4.11 Mn |
| Sep 30, 2011 | -4.11 Mn |
| Jun 30, 2011 | -6.84 Mn |
| Jun 30, 2011 | -6.84 Mn |
| Mar 31, 2011 | -8.56 Mn |
| Mar 31, 2011 | -8.56 Mn |
| Dec 31, 2010 | 6.57 Mn |
| Dec 31, 2010 | 6.57 Mn |
| Sep 30, 2010 | -6.05 Mn |
| Sep 30, 2010 | -6.05 Mn |